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Abstract
Background: The role that nitric oxide (NO) plays in modulating pain in the periphery is unclear. We show here,
the results of two independent clinical studies (microdialysis and gene expression studies) and a pilot dose finding
study (glyceryl trinitrate study), to study the role of NO in the early phase of acute inflammatory pain following oral
surgery. The effect of ketorolac on NO production and nitric oxide synthase (NOS) gene expression was also
studied.
Results: Microdialysis samples showed significantly higher levels of NO at the first 100 min compared to the last
80 minutes in the placebo treated group. In the ketorolac group, on the other hand, NO levels gradually decreased
over the first 60 min but were similar to placebo over the later 100-180 min, with no significant change in NO
level over time. The levels of NO were negatively correlated to pain intensity scores. Local infusion of the NO
donor glyceryl trinitrate at the site of surgery, showed a small analgesic effect that did not reach statistical
significance in the sample size used. While the gene expression of iNOS and eNOS were not up-regulated, 3 hours
after surgery, nNOS was downregulated in both treatment groups and eNOS gene expression was significantly
lower in the ketorolac group compared to the placebo group. Further, there was a positive correlation between
the change in gene expression of nNOS and eNOS in the placebo goup but not in the ketorolac group.
Conclusion: We suggest that at this early stage of inflammatory pain in man, NO is analgesic in the periphery.
Further, ketorolac down-regulates eNOS gene expression.
Background
Nitric oxide (NO) is involved in numerous physiological
processes in the peripheral and central nervous system
[1]. It is produced intracellularly by the catabolism of L-
arginine to L-citrulline by NO synthase enzyme (NOS),
which is present in three isoforms, the neuronal
(nNOS), endothelial (eNOS) and inducible (iNOS) iso-
forms. The role that NO plays in pain is not simple,
since it may show pro- or anti-nociceptive effects
depending on the circumstances [2]. The majority of
data, in preclinical studies support a pronociceptive role
of NO at the spinal level [3-6]. Yet, other studies show
inconsistent results; for review see [7].
The effect of NO on pain and analgesia in the periph-
ery is further conflicting. Sodium nitroprusside, which
releases NO non-enzymatically, has an antihyperalgesic
effect in the rat paw pressure test [8]. Conversely,
intradermal administration of the NOS substrate L-Arg
or the NO donor SIN-1, both of which elevate NO
levels, cause a dose-dependent mechanical hyperalgesia
[9]. Conflicting clinical effects are also reported; as
intracutaneous injection of NO in healthy volunteers
evokes pain in a dose dependent manner [10], while
transdermal application of the NO donor glyceryl trini-
trate improved pain in patients with shoulder pain syn-
drome [11]. Associations between NO levels and pain
intensity also show conflicting results. While there was
no association between NO concentration in the perifa-
cetal region and pain duration or pain level in patients
with chronic low back pain [12], NO correlated with
pain in the polyarticular subtype of juvenile idiopathic
arthritis with active disease[13].
The role of different NOS isoforms in inflammatory
pain process is derived primarily from animal experi-
ments [2]. While nNOS is mainly observed at the spinal
level or in neuropathic pain models, iNOS is up-regu-
lated in inflamed tissues [14] and is involved in the
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development of hyperalgesia in inflammatory and neuro-
pathic pain models [15]. Knockout mice, providing
another tool for the identification of the specific role of
each isoform in different pain models, confirm the role
of nNOS and iNOS isoforms [16-18]. However, studies
performed on knockout mice as well as those using dif-
ferent selective and non-selective NOS inhibitors point
to a possible role for eNOS isoform in pain processing
[16,17].
NSAIDs are among the most prescribed medications,
yet their efficacy is compromised by a ceiling analgesic
effect. The inhibitory effect of NSAIDs on NO produc-
tion has been reported in many studies both clinically
[19] and experimentally [5,20] and the involvement of
the NO-cGMP pathway in the antinociceptive effects of
NSAIDs has been suggested in several experimental stu-
dies [21,22].
The aim of the present study was to investigate the
role of NO and NOS isoforms in acute inflammatory
pain induced by a clinically well-defined model of clini-
cal pain, third molar extraction. The effect of the
NSAID ketorolac on NO production and NOS gene
expression was also studied. To achieve this goal, two
independent studies as well as a third pilot dose finding
study were carried out: (1) a microdialysis study to esti-
mate changes in NO levels at the site of tissue injury
and to correlate these levels to pain intensity reported at
the same time points; (2) a gene expression study to
determine change in gene expression of the three NOS
isoforms at the site of tissue injury, and finally (3) the
glyceryl trinitrate glyceryl trinitrate study, which aimed
at finding an efficacious dose to study the effect of the
NO donor glyceryl trinitrate on pain intensity following
tissue injury.
Results
I. Association between NO level at the site of tissue injury
and pain intensity
A. Pain intensity following tissue injury
Pain intensity as evaluated by visual analogue scale
(VAS) showed a continuous increase over the 3 hours
observation period (Figure 1a). The repeated measure
two way ANOVA model, controlling for time and the
random effects of patients, detected a significant differ-
ence in pain intensity between placebo and ketorolac
treated patients (p = 0.018, n = 24 & 20 for placebo and
ketorolac, respectively).
B. NO levels at the site of tissue injury
NO levels at the surgical site were evaluated every
20 min following tissue injury using microdialysis collec-
tion. Patients that had more than one sample missing
from the set of 9 serial samples due to failure of micro-
dialysis probe, blood contamination of the sample or a
low sample volume that did not allow analysis of
replicates were excluded from this analysis. As seen in
Figure 1b, NO levels gradually increased over the first
80 min in the placebo-treated group before declining
gradually over the last 100 min of the observation per-
iod, reaching its lowest level by the end of the 3 hours
collecting period. Contrast analysis under the linear
mixed effects model controlling for time shows that NO
levels over the first 100 min were significantly higher
than those over the last 80 min (p < 0.0001) in the pla-
cebo treated group. NO level in microdialysate in sub-
jects administered ketorolac before surgery gradually
decreased over the first 60 min but was similar to pla-
cebo over the 100-180 min observations. Although,
Figure 1 Microdialysis Study . (a) Effect of tissue injury and
ketorolac treatment on pain intensity following third molar tooth
extraction (p = 0.018; repeated measure two way ANOVA, n = 24 &
20 for placebo and ketorolac treatment groups, respectively). (b)
Effect of tissue injury and ketorolac treatment on NO production at
the site of oral surgery. Data are presented as mean ± SEM; n = 19
& 10 for placebo and ketorolac treatment groups, respectively;
*indicates the first five time points were significantly different from
the last four time points, p < 0.0001; contrast analysis under the
mixed linear model. Raw data were not normally distributed so
were transformed to ln(VAS+1) and statistical analysis were
conducted on transformed data.
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there was no significant change in the NO levels over
time in the ketorolac group, the difference between the
two treatment groups was not statistically significant
(p = 0.48).
C. Correlation between pain intensity and NO levels
Because both pain intensity and NO levels were
reported repeatedly in the same patients, simple correla-
tion analysis would have ignored this fact and would
have tested the correlation considering each time point
as a different patient. Further, it would have ignored the
difference in the time of collection or reporting of pain.
Therefore linear mixed effects model was fitted to over-
come both problems and to further test interaction of
treatment and NO levels on pain intensity.
Only pain intensity scores for patients with successful
microdialysis sampling (n = 19 & 10 for placebo and
ketorolac, respectively) were included in the analysis.
Under the linear mixed model with covariates time,
treatment, NO, and the interaction of treatment and
NO, NO was found to be negatively correlated to pain
scores (regression coefficient = -0.6782, p = 0.0014,
Table 1).
II. Effect of the NO donor glyceryl trinitrate on pain
intensity
This study was a pilot dose finding study that aimed at
finding the appropriate dose and sample size to further
confirm the analgesic role of NO by administering the
NO donor glyceryl trinitrate following tissue injury. Pla-
cebo or glyceryl trinitrate was infused directly into the
site of surgery using PE 50 tubing. Three doses of
glyceryl trinitrate were tried, none of which produced a
significant analgesic effect (Figure 2a).
However, when two groups (150 and 200 μg) were
pooled, there was a significant difference between the
placebo and glyceryl trinitrate treated patients over the
1 hour observation period (p = 0.038, repeated measure
two way ANOVA; n = 20 & 37 for placebo and glyceryl
trinitrate groups, respectively; Figure 2b). Further, when
the sum of pain intensity reported by each patient over
the one hour observation period were plotted against
the dose of glyceryl trinitrate, considering placebo as
zero μg, this resulted in a linear dose response that sig-
nificantly deviated from zero (p = 0.044) and that
showed a negative slope of -0.60 ± 0.29; linear regres-
sion; Figure 2c).
Power analysis of the data, showed a required sample
size of 47 patients per group in order to achieve an 80%
power to show a difference between the sum of VAS
over one hour observation period of the placebo and
glyceryl trinitrate groups. Given the small effect size, the
large sample size required and the increased rate of
headache with the use of these doses of glyceryl trini-
trate, a larger study was not conducted for ethical
consideration.
III. Effect of tissue injury and ketorolac treatment on the
gene expression of NOS isoforms
A. Change in gene expression
We further studied the role of NO on acute inflamma-
tory pain by measuring the change in gene expression of
the 3 NOS isoforms using qRT-PCR. nNOS was signifi-
cantly down-regulated in both the placebo group (2.4
fold; p = 0.02; paired t-test) and the ketorolac treatment
group (3.4 fold; p = 0.0003; paired t-test). However,
there was no significant difference between the two
treatment groups (Figure 3a).
On the other hand, iNOS did not show any significant
change compared to the pre-surgery level neither in the
placebo group (p = 0.7) nor in the ketorolac treatment
group (p = 0.98).
As for eNOS gene expression levels, there was a small
insignificant change in both treatment groups when
compared to the pre-surgery biopsies (p = 0.17 and 0.23
for the placebo and ketorolac treatment groups, respec-
tively). However, these small changes being in opposite
directions resulted in a significant difference between
the two treatment groups (p = 0.026, independent two-
sample t-test).
B. Correlation between the gene expression of NOS
isoforms
The correlation between the changes in gene expression
of the three NOS isoforms following tissue injury was
examined using Pearson’s correlation coefficients (Fig.
3b&3c). The gene expression of nNOS and eNOS were
significantly correlated in the placebo group (r = 0.56;
p = 0.038; n = 14; Fig. 3b), but not in the ketorolac
Table 1 Mixed linear model analysis solution for fixed
effects on pain intensity
Effect TTT Estimate Error DF t Value Pr > |t|
Intercept 3.5634 0.4854 25 7.34 < .0001
T1 -2.3715 0.2329 201 -10.18 < .0001
T2 -2.3553 0.2252 201 -10.46 < .0001
T3 -1.9908 0.2243 201 -8.88 < .0001
T4 -1.3578 0.2276 201 -5.97 < .0001
T5 -1.0752 0.2217 201 -4.85 < .0001
T6 -0.6795 0.2174 201 -3.12 0.0020
T7 -0.2980 0.2161 201 -1.38 0.1696
T8 -0.1076 0.2162 201 -0.50 0.6193
T9 0
Treatment Placebo 0
Treatment Ketorolac 0.3034 0.5885 201 -0.52 0.6067
NO -0.6782 0.2099 201 -3.23 0.0014
NO * treatment Placebo 0
NO * treatment Ketorolac -0.8911 0.2632 201 3.39 0.0009
* Data analyzed included patients with successful microdialysis, only.
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treatment group (r = 0.004; p = 0.99; n = 14; Fig. 3c).
There was no significant correlation between the
changes in gene expression of iNOS and either of the
two other isoforms (data not shown).
Discussion
As mentioned earlier, NO has been mostly considered as a
pain mediator. However, we show here in a clinical study
that NO is not only devoid of this pronociceptive property
in the periphery, at this early stage of acute inflammatory
pain, but it is also negatively correlated to pain.
The unresolved role of NO in nociception at the per-
iphery [8,9] has been attributed in animal studies to sev-
eral factors, including the level of NO. Low levels of NO
at the site of injury show antinociceptive effects, whereas
higher concentrations have pronociceptive effects. In a
rat model of incisional pain, the NO donor, S-nitroso-
N-acetylpenicillamine (SNAP) applied inside the surgical
Figure 2 Glyceryl trinitrate Study. (a) Effect of glyceryl trinitrate (100, 150 or 200 μg) on pain intensity when infused into the surgical site of
third molar tooth extraction over 20 min (n = 18-20 per group). (b) Effect of glyceryl trinitrate (150 or 200 μg) on pain intensity when infused
into the surgical site of third molar tooth extraction over 20 min n = 20 & 37 for the placebo and glyceryl trinitrate groups respectively; p =
0.038; repeated measure 2 way ANOVA. (c) Dose response curve of glyceryl trinitrate’s effect on pain intensity when infused into the surgical site
of third molar extraction. Linear regression shows a slope significantly different from zero (n = 18-20 per group).
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wound, reduced the incision allodynia at concentrations
between 1-10%. On the other hand, higher concentra-
tion (30%) intensified the allodynia [23]. The same find-
ing was seen in the formalin test [24].
Baseline level of neuronal excitability is also
thought to affect the role of NO in nociception [25].
Electrophysiological recordings of dural nociceptive
afferents showed that neurons with higher mechanical
activation thresholds were activated by NO donors,
while neurons with lower mechanical activation thresh-
olds were inhibited by NO donors [25]. Further, in
PGE2 induced pain, the NO donor SIN-1 induced a
dose dependent hypernociception when injected intra-
dermally, while inducing an antinociceptive effect
when injected subcutaneously, which suggests that dif-
ferent subsets of primary nociceptive neurons may
respond differently to NO [26].
The NOS isoform expressed at the site of injury might
also contribute to identifying the role of NO in nocicep-
tion. The role of different NOS isoforms in pain proces-
sing is still subject to debate. It is known that nNOS
and eNOS, though found primarily within the nervous
system and endothelial tissue respectively, are also
found in other tissues, whereas iNOS is expressed in
various cell types, such as macrophages and neutrophils
[6]. In the present study, the three NOS isoforms were
expressed in the gingival mucosa, following tissue injury.
While both nNOS [16,17,27] and iNOS [27,28] are fre-
quently suggested to play an important pronociceptive
role in several pain models, eNOS is not often studied.
However, it was reported that eNOS was the only iso-
form involved in both phases of the rat formalin test
[17] and eNOS-/- mice showed a more rapid recovery
from thermal hyperalgesia compared to wild type mice
after intraplantar injection of complete Freund’s adju-
vant [16]. Interpretation of findings in NOS-/- mice is
compromised by the compensation of other isoforms for
the deficient isoform [16,29,30], at least at the spinal
level. The analgesic role of NO at the periphery may be
explained by the fact that NO generated by eNOS may
modulate leucocyte adherence, which contributes to
inflammation [31] and pain [32]. NO is also responsible
for vasodilatation with subsequent increased blood sup-
ply to the injured region and ultimately increased clear-
ance of local inflammatory mediators [33], another
possible mechanism for the analgesic effect of NO at
the periphery.
The down-regulation of nNOS in both treatment
groups seen here is an interesting finding that may
reflect a feedback effect to the higher NO levels at ear-
lier time points. However, the present data cannot indi-
cate such a conclusion. Since the increase in NO
production seen in the microdialysis samples occurred
during the first 80 min, this may explain the minimal
change noticed at the gene expression level of NOS iso-
forms at 3 hours. Therefore, further investigation to
study the effect of tissue injury on NOS isoforms at ear-
lier and latter time points is warranted. However, the
gene expression results suggest a relatively low level of
NO at the site of injury, given the down regulation of
Figure 3 Gene expression study. (a) Tissue injury resulted in the
down-regulation of gene expression of nNOS 2.4-fold in the
placebo group and 3.4-fold in the ketorolac group. eNOS was
insignificantly up-regulated in the placebo group, but down-
regulated in the ketorolac group, with significant difference
between the two treatment groups. The changes in gene
expression following tissue injury were assessed by qRT-PCR. The
gene expression level is expressed as fold change relative to pre-
surgery level. *indicates p = 0.02; **indicates p = 0.0003 compared
to pre-surgery group (paired t-test); #indicates p = 0.026 compared
to the placebo group (independent-sample t test). (b & c) The
relative changes in gene expression (RQ) from qRT-PCR of eNOS and
nNOS were correlated in the placebo group but not in the ketorolac
treated group. The association was examined using Pearson
correlation at 3 hours post-surgery.
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nNOS and insignificant change of the other two
isoforms.
Taking into account the negative correlation between
NO levels and pain intensity reported here, it is plausi-
ble that at lower levels, NO released at the periphery
plays an analgesic role in this clinical model of inflam-
matory pain (Fig. 4).
Another interesting finding in the present study is the
correlation between nNOS and eNOS expression in the
placebo, but not in the ketorolac treatment group,
which suggests an inhibitory effect of ketorolac on
eNOS gene expression. To our knowledge, the associa-
tion between the expression of these two isoforms has
not been reported earlier. It is known that both nNOS
and eNOS are constitutive isoforms of NOS that are cal-
cium-dependent [2]. We have recently reported the
upregulation of kinin B1 and B2 receptors at the same
pain model and time frame [34], both of which cause
elevated free intracellular calcium upon activation [35]
that may contribute to the activation of both NOS iso-
forms. The down regulation of eNOS by NSAIDs, on
the other hand, is in line with the suppression of eNOS
expression by high-dose aspirin or meloxicam, in retinas
of diabetic rats [36].
The negative correlation between NO levels and pain
intensity that we show here, is in line with the analgesic
effect of topical glyceryl trinitrate that was reported ear-
lier in several tendinopathies [11,33,37,38]. Unfortu-
nately, we could not show the same analgesic effect of
glyceryl trinitrate in the present study as the infusion of
a rather small dose of glyceryl trinitrate (150 or 200 μg)
into the surgical site did not show a significant analgesic
Figure 4 Tissue injury increases NO production possibly via eNOS or nNOS in the early phase following surgery. This causes a small
increase in NO level that lead to an analgesic effect. However, in the late phase iNOS isoform is up-regulated, producing a marked increase in
NO level that would have a hyperalgesic effect. cNOS, constitutive NOS.
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effect at the sample size used. However, combining both
groups resulted in a small analgesic effect. It was not
possible to further increase the dose of glyceryl trinitrate
to examine a dose dependent nature of NO effect on
pain, nor to extend the study due to ethical concerns,
given the small analgesic effect and the associated
increased rate of headache with glyceryl trinitrate
infusion.
It is not clear, why infusion of glyceryl trinitrate in
the present study did not achieve a clear analgesic
effect, in contrast to the earlier studies [11,33,37,38].
However, it is possible that to reach a detectable
analgesic effect, longer exposure to NO is required,
given in our study glyceryl trinitrate was infused for
20 min only, while in earlier studies, patients received
transdermal glyceryl trinitrate patch for at least three
days and up to 24 weeks.
There is a great body of evidence that supports an
inhibitory role of NSAIDs on NO production both in
clinical and experimental settings [19,39-41]. However,
some studies suggest a stimulatory role e.g. [42,43] and
others did not show any effect [44]. This variability
might be due to different experimental settings, includ-
ing selectivity of NSAID, concentration used, stimulants
and cell type, which may reflect on the NOS isoform
expressed. Nevertheless, most of the studies showing an
inhibitory effect of NSAIDs on NO production also
show downregulation of iNOS expression. Since in the
present study iNOS isoform was not up-regulated,
3 hours following tissue injury, this may explain the fail-
ure of ketorolac to decrease NO production at this early
time point. Even though ketorolac down-regulated
eNOS expression, this did affect NO levels, possibly
because eNOS generate small amounts of NO, com-
pared to iNOS [2], which makes the effect of ketorolac
on NO production rather small.
We therefore suggest that at this early phase of
inflammatory pain, NO plays an analgesic role in the
periphery. Further studies are needed to identify the
contribution of NOS isoforms to this analgesic effect.
Methods
Subjects and procedures
The present work shows the results of two independent
studies: a microdialysis study, and a gene expression
study. A third, dose finding, pilot study was also con-
ducted, glyceryl trinitrate intervention study. Participants
in these three independent studies were healthy volun-
teers (n = 147) aged between 16 and 36 years, who
required extraction of impacted third molars. Demo-
graphic data of participants in each study are shown in
Table 2, 28 other subjects, who did not develop moder-
ate pain following surgery, were excluded from the gly-
ceryl trinitrate study. Protocols for the three studies
were approved by the Institutional Review Board of
NIDCR/NIH. Written informed consent was obtained
from all participants before treatment. Pregnant or lac-
tating females or patients with the presence of clinical
signs of infection or inflammation at the extraction sites
were not included in the study. All subjects received
intravenous midazolam (4.1 ± 1 mg) and local anesthe-
sia by 2% lidocaine (151.3 ± 25.8 mg) with epinephrine
1:100,000 prior to surgery. Following ethical regulations,
a rescue analgesic drug was provided upon patient’s
request in both the microdialysis and gene expression
studies. The observation period in case of the glyceryl
trinitrate study was one hour, so rescue medicine was
not permitted during this hour.
Microdialysis procedure
Following satisfactory local anesthesia, subjects ran-
domly received either ketorolac (30 mg) or placebo
Table 2 Demographic data of participants
Protocol Microdialysis Glyceryl trinitrate Gene Expression
All subjects Successful sampling
Treatment Placebo Ketorolac Placebo Ketorolac Placebo 100 μg 150 μg 200 μg Placebo Ketorolac
Number 24 20 19 10 20 18 19 18 15 13
Age 20.4 ± 3.9 19.0 ± 2.4 19.9 ± 3.3 20.0 ± 2.7 22.9 ± 5.4 20.1 ± 3.6 22.0 ± 4.9 22.4 ± 5.4 19.3 ± 3.5 18.9 ± 2.8
Gender M/F 7/17 5/15 3/15 1/8 15/5 12/6 9/10 9/9 8/7 8/5
Race
White 18 14 12 6 15 12 13 14 13 10
African 3 3 3 2 1 4 2 2 – 2
Others 3 3 3 1 4 2 4 2 2 1
Difficulty* 3.5 ± 0.6 3.5 ± .05 3.5 ± 0.6 3.5 ± 0.5 2.95 ± 0.8 3.2 ± 0.9 3.4 ± 0.8 3.3 ± 0.7 7.3 ± 0.9 7.2 ± 0.9
Rescue Medicine 14 (58%) 6 (30%) 11 (61%) 3 (33%) N/A N/A N/A N/A 9 (60%) 5 (38%)
Data presented as mean ± S.D.
* Extraction difficulty is the sum calculated by assigning a score of (2) for soft tissue impactions, (3) for partial bony impactions and (4) for full bony impactions.
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intravenously immediately before surgery. Two mandib-
ular third molars were extracted and a surgical difficulty
score was assigned for each tooth. After extraction, a
microdialysis probe (CMA/20 Microdialysis Probe;
CMA/Microdialysis, North Chelmsford, MA) was placed
along the buccal aspect of the mandible, beneath the
mucogingival flap elevated for the surgical procedure
[45,46]. The probe fiber consists of a 10-mm flexible,
nonmetallic, semipermeable dialysis membrane with a
molecular cutoff ranging from 3000 to 20,000 Da. The
probes were secured to an adjacent tooth with silk
suture and the flap closed using 3-0 chromic gut suture.
Sterile lactated Ringer’s solution was pumped at 10 μL/
min and samples collected at 20-min intervals after the
completion of surgery. The samples were immediately
placed on dry ice after each collection period. Subjects
remained under observation for the first 3 hours after
surgery to evaluate pain and adverse events and for col-
lection of samples by microdialysis. Patients rated their
pain intensity every 20 min for the first 3 h post-opera-
tively using 100-mm visual analog scale (VAS). At the
conclusion of the observation period, the microdialysis
probes were removed and the samples were stored at
-70°C.
Glyceryl trinitrate administration
Only patients who developed moderate pain (≥ 35 on
the VAS) following surgery and disappearance of local
anesthetic effect were included in this protocol. A PE50
tubing was placed under the flap elevated for tooth
extraction. Three different doses of glyceryl trinitrate
(100 μg, 150 μg or 200 μg) prepared in a final volume
of 1 ml or a placebo were delivered over 20 min to the
surgical site. These doses were selected based on the
analgesic effect of transdermal glyceryl trinitrate in
shoulder pain syndrome due to supraspinatus tendinitis
[11]. Since this was a pilot study, with no previous
experience of the possible effect size, there was no sam-
ple size calculation prior to conducting this study. The
number of patients enrolled was based on previous
experience with the oral surgery model. Pain was evalu-
ated using 100 mm VAS for 1 hour following drug
delivery.
Gene expression analysis by qRT-PCR
In this protocol, two impacted third molars were
extracted. A 3 mm punch biopsy was taken from the
oral mucosa overlying one impacted third molar imme-
diately prior to surgery and a second biopsy was taken
from the opposite surgical site 3 hours post-surgery. All
biopsies were immediately frozen in liquid nitrogen and
stored at -70°C until ready for RNA extraction. Patients
received a placebo or ketorolac 30 minutes prior to
surgery.
Oral mucosal biopsies (n = 64) were used to detect
gene expression using ABI Prism 7900 HT Sequence
Detection System (Applied Biosystems, Foster City, CA)
as described previously [45,47,48]. All reagents were
purchased from Applied Biosystems and 2 μg of DNase-
treated RNA was used to synthesize cDNA using ran-
dom primers from the High-Capacity cDNA Archive Kit
according to the manufacturer’s instruction. Polymerase
chain reaction was performed with cDNA template
using the PCR Master Mix with AmpErase UNG.
Sequence-specific primers and TaqMan MGB probes
were purchased from Assays-on-Demand Gene expres-
sion product. Quantification of gene expression was per-
formed in a 20-μL reaction (384-well plate) and each
sample was run in triplicate. The housekeeping gene
18S rRNA was used as endogenous control and negative
controls were processed under the same conditions
without a cDNA template. Data acquisition was con-
ducted using User Bulletin #2 software (v1.6, Applied
Biosystems). The threshold cycle (Ct) of 18 rRNA was
used to normalize target gene expression (ΔCt) to cor-
rect for experimental variations. The relative change in
gene expression (ΔΔCt) was used for comparison of the
gene expression in post-surgery tissue versus that in
pre-surgery tissue.
Measurement of NO degradation products
NO has a very short half-life and is quickly degraded in-
vivo to its stable end-products nitrite and nitrate. Nitrite
and nitrate (NOx) as an index of total NO production
were measured in microdialysis samples using a com-
mercially available kit (Nitrate/Nitrite Fluorometric
Assay Kit, Cayman Chemical Company, Ann Arbor,
MI), following the manufacturer’s instructions. Samples
containing blood were excluded as blood interfers with
accurate evaluation of nitrite and nitrate levels using
fluorometry. The samples were run in triplicate and
fluorescence was read using a Victor3 Perkins Elmer
spectrofluorometer (excitation = 370 nm; emission =
420 nm).
Fluorometric assay for NOx measurement is more
sensitive than the conventional colourimetric assays
based on Griess reaction and both methods were found
to produce essentially the same results [49].
Statistical analysis
Statistical analysis was carried out using SAS (v. 9.1,
SAS Institute Inc., Cary, NC) or SPSS (v. 16.0, SPSS,
Chicago, IL). Demographic data, such as age and gender,
were summarized for different treatment groups. Mean
and SEM of NO and VAS were plotted for ketorolac
and NTG treatment at 9 time points. Glyceryl trinitrate
dose response was evaluated using linear regression.
Comparisons between effects of ketorolac or glyceryl
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trinitrate treatment and placebo on VAS were per-
formed using repeated measure two-way ANOVA. Lin-
ear mixed effects models were fitted to investigate the
effect of time (at 9 levels), treatment, NO and the inter-
action effect between treatment and NO on VAS for the
microdialysis study. Patient ID was assumed to be a ran-
dom effect and each patient had a random intercept in
all the linear mixed models since the samples were
pulled out from a large population. The effect of treat-
ment on NO production was also examined using linear
mixed effect models. Data that did not follow normal
distribution was transformed to ln(x+1). The relative
change in gene expression was assessed by paired t-test,
and the comparison between treatment groups was
assessed by independent two-sample t test and the asso-
ciation among these gene expressed was examined by
Pearson’s correlation coefficients. Results were consid-
ered significant at a = 0.05.
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